IDEAYA生物科學股票討論區

$IDEAYA生物科學(IDYA.US)$ IDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR+, Her2-, BRCA1/2 mutant Breast Cancer

$IDEAYA生物科學(IDYA.US)$@Alvinnnnnnn89@AmyNic@Ripper1986
starting to look good from a rookie persoe tive. Thanks in advance.

$IDEAYA生物科學(IDYA.US)$@AmyNic@Ripper1986 great day. in at 18.3
Thanks to peeps pushing me to be better.

Netflix Upgraded to Buy From Sell at CFRA
CFRA analyst Kenneth Leon double upgraded $奈飛(NFLX.US)$ to Buy from Sell with a price target of $310, up from $225. The analyst believes it "will be difficult for competitors to catch" Netflix, noting it is one of the few profitable streaming providers with global scale.
Capital One Starts Ideaya Biosciences at Overweight With $29 Price Target
Capital One analyst Zegbeh Jallah initiated...

Gapping up
Select biotech/pharma names showing strength following ESMO:
$Clovis Oncology(CLVS.US)$ +11.3%, $Cardiff Oncology(CRDF.US)$ +9%, $Immatics(IMTX.US)$ +8.3%, $IDEAYA生物科學(IDYA.US)$ +8%, $Lyra Therapeutics(LYRA.US)$ +5.7%, $POINT Biopharma(PNT.US)$ +5.7%, $Edgewise Therapeutics(EWTX.US)$ +4.7%, $Concert Pharmaceuticals(CNCE.US)$ +3.6%, $Deciphera Pharmaceuticals(DCPH.US)$ +3.2%, $Veracyte(VCYT.US)$ +2.6%, $SpringWorks Therapeutics(SWTX.US)$ +2.3%,...

Gapping up
In reaction to earnings/guidance:
• $聯電(UMC.US)$ +0.8% (August revs)
Other news:
• $ChannelAdvisor(ECOM.US)$ +54.4% (to be acquired for $23.10 per share)
• $IVERIC bio(ISEE.US)$ +42.3% (topline data from Zimura GATHER2 phase 3 clinical trialingeographic atrophy)
• $Monte Rosa Therapeutics(GLUE.US)$ +10% (receives FDA clearance of Investigational New Drug Application for MRT-2359)
• $IDEAYA生物科學(IDYA.US)$ +4.9% (re...

$IDEAYA生物科學(IDYA.US)$ pkc1 cmet combo MAY produce similar or better result than tebentafusp

Gainers:
• $Kezar Life Sciences(KZR.US)$ +92% (announces positive top line results from the MISSION Phase 2 trial)
• $Sutro Biopharma(STRO.US)$ +24.5% (Sutro Biopharma and Astellas to collaborate to advance novel immunostimulatory antibody-drug conjugates)
• $Ceragon(CRNT.US)$ +17.7% (AVNW to acquire all shares of CRNT that it does not already own for $2.80/sh)
• $攜程網(TCOM.US)$ +15.6% (In reaction to earnings/guidance)
• $Apyx Medical(APYX.US)$ +8% (anno...